NCT06505291

Brief Summary

The main objective of this work is to evaluate the prevalence and results of specific management of HCC after spontaneous rupture, since the arrival of sorafenib in 2008.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
112

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2008

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2008

Completed
15.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2023

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 25, 2024

Completed
22 days until next milestone

First Posted

Study publicly available on registry

July 17, 2024

Completed
Last Updated

July 17, 2024

Status Verified

April 1, 2024

Enrollment Period

15.7 years

First QC Date

June 25, 2024

Last Update Submit

July 10, 2024

Conditions

Hepatocellular Carcinoma

Outcome Measures

Primary Outcomes (1)

  • Survival after rupture of hepatocellular carcinoma

    15 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient with ruptured hepatocellular carcinoma

You may qualify if:

  • Ruptured hepatocellular carcinoma with or without cirrhosis

You may not qualify if:

  • Liver adenoma without histologically proven HCC
  • Other benign or malignant liver tumors
  • ATCD of potentially triggering interventional procedure in the previous month.
  • Hemorrhagic ascites without tumor
  • Intratumoral hemorrhages without hemoperitoneum or capsular rupture

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Commin A, Metivier C, Allaire M, Lubrano J, Claudinot A, Coilly A, Allard MA, Roux C, Scatton O, Nault JC, Sutter O, Ganne-Carrie N, Ngo TV, Goff VL, Ali ZB, Tedlaouti H, Papin J, Habireche M, Lebedel L, Perignon C, Dao T, Morello R, Ollivier-Hourmand I. Early Hemostatic Treatment Could Improve 30-Day Survival After Spontaneous Rupture of Hepatocellular Carcinoma. Liver Int. 2025 Oct;45(10):e70332. doi: 10.1111/liv.70332.

    PMID: 40990229DERIVED

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
OTHER
Target Duration
16 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 25, 2024

First Posted

July 17, 2024

Study Start

January 1, 2008

Primary Completion

September 1, 2023

Study Completion

April 30, 2024

Last Updated

July 17, 2024

Record last verified: 2024-04